You are here: Home » Markets » News
Business Standard

Vivimed Labs surges on successful USFDA inspection of Alathur facility

The stock surged 16% to Rs 107 on the BSE in early morning trade on back of heavy volumes.

SI Reporter  |  Mumbai 

Zydus acquires derma brand Melgain from Issar Pharma

has surged 16% to Rs 107 on the BSE in early morning trade after the company said its 'Finished Dosage Form' (FDF) manufacturing facility located in Alathur, near Chennai has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection.

The audit was conducted during the last week of November and concluded on November 28, 2016.


The company also obtained ANDA approval for Metronidazole and same is commercialized, said in a release.

During November 2016, the Company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4 FY2O17, it added.

Commenting on the development, MD Santosh Varalwar said: "Over the two years we have received satisfactory outcomes of inspections for our two plants in Spain, one in Mexico and one in India."

For the India plant, this was the second inspection, he added.

At 09:3 am; the stock was up 12.5% at Rs 104 on the BSE, as compared to 0.21% rise in the S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 1.17 million shares changed hands on the BSE and NSE so far.
 

RECOMMENDED FOR YOU

Vivimed Labs surges on successful USFDA inspection of Alathur facility

The stock surged 16% to Rs 107 on the BSE in early morning trade on back of heavy volumes.

The stock surged 16% to Rs 107 on the BSE in early morning trade on back of heavy volumes.
has surged 16% to Rs 107 on the BSE in early morning trade after the company said its 'Finished Dosage Form' (FDF) manufacturing facility located in Alathur, near Chennai has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection.

The audit was conducted during the last week of November and concluded on November 28, 2016.

The company also obtained ANDA approval for Metronidazole and same is commercialized, said in a release.

During November 2016, the Company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4 FY2O17, it added.

Commenting on the development, MD Santosh Varalwar said: "Over the two years we have received satisfactory outcomes of inspections for our two plants in Spain, one in Mexico and one in India."

For the India plant, this was the second inspection, he added.

At 09:3 am; the stock was up 12.5% at Rs 104 on the BSE, as compared to 0.21% rise in the S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 1.17 million shares changed hands on the BSE and NSE so far.
 

image
Business Standard
177 22

Vivimed Labs surges on successful USFDA inspection of Alathur facility

The stock surged 16% to Rs 107 on the BSE in early morning trade on back of heavy volumes.

has surged 16% to Rs 107 on the BSE in early morning trade after the company said its 'Finished Dosage Form' (FDF) manufacturing facility located in Alathur, near Chennai has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection.

The audit was conducted during the last week of November and concluded on November 28, 2016.

The company also obtained ANDA approval for Metronidazole and same is commercialized, said in a release.

During November 2016, the Company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4 FY2O17, it added.

Commenting on the development, MD Santosh Varalwar said: "Over the two years we have received satisfactory outcomes of inspections for our two plants in Spain, one in Mexico and one in India."

For the India plant, this was the second inspection, he added.

At 09:3 am; the stock was up 12.5% at Rs 104 on the BSE, as compared to 0.21% rise in the S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 1.17 million shares changed hands on the BSE and NSE so far.
 

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard